Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Get Free Report) saw unusually-strong trading volume on Monday . Approximately 159,528 shares traded hands during mid-day trading, an increase of 740% from the previous session's volume of 18,989 shares.The stock last traded at $22.86 and had previously closed at $19.50.
Analysts Set New Price Targets
A number of research analysts recently issued reports on TLX shares. UBS Group lifted their price target on shares of Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Monday, January 27th. William Blair upgraded shares of Telix Pharmaceuticals Limited American Depositary Shares to a "strong-buy" rating in a report on Tuesday, November 19th.
View Our Latest Stock Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Stock Down 2.0 %
The firm has a 50 day simple moving average of $16.98.
About Telix Pharmaceuticals Limited American Depositary Shares
(
Get Free Report)
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
See Also
Before you consider Telix Pharmaceuticals Limited American Depositary Shares, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals Limited American Depositary Shares wasn't on the list.
While Telix Pharmaceuticals Limited American Depositary Shares currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
